REUTERS: Amgen Inc's push to get patients on its new US$575 a month migraine drug before competition emerges in September is facing barriers from insurers. Bracing for a flood of costly prescription claims for the drug, Aimovig, large insurers such as Anthem Inc have set requirements for patients ...
from Latest News https://ift.tt/2NJhnlW
Amazon Fire TV Stick with...
Subscribe to:
Post Comments (Atom)

No comments:
Post a Comment